CPChristopher G. Przybycin

Christopher G. Przybycin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher G. Przybycin has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression

    by Jane K Nguyen, Marcello P Toscano, Jianbo Li, Sean R Williamson, Christopher G Przybycin, Chia‐Sui Kao, Jonathan L Myles, Kristýna Pivovarčíková, Marián Švajdler, Marek Brousil, et al.

    Objective: Histological grading is a key predictor of progression in non‐muscle‐invasive bladder cancer (NMIBC). The WHO 1973 three‐tier system is limited by heterogeneity within the G2 category, whereas the WHO 2004/2016 binary classification reduces prognostic resolution by grouping biologically diverse tumours into broad low‐grade (LG) and high‐grade (HG) categories. We aimed to evaluate the prognostic performance of hybrid grading systems compared with WHO 2004/2016, while further characterizing the histomorphological continuum of non‐invasive papillary urothelial carcinoma. Methods: Non‐invasive papillary urothelial carcinomas (2012–2023; n = 472) were reviewed and reclassified by two urological pathologists according to WHO 2004/2016, hybrid three‐tier and four‐tier systems, and an investigational five‐tier framework (Grades I, IIA, IIB, IIIA, IIIB) integrating architectural, cytological and proliferative features. Primary endpoints were recurrence, grade progression and T1+ stage progression, assessed using ROC analysis, Cox proportional hazards regression and model‐performance metrics (AIC, BIC, C‐index). Results: Increasing morphological atypia was associated with larger tumour size, greater multifocality and progressively higher progression risk, with events concentrated in Grades IIIA and IIIB. All systems showed limited recurrence discrimination (C‐index 0.54–0.56). For T1+ progression, discrimination improved with increasing stratification (AUC 0.754 for WHO 2004/2016 vs. 0.815, 0.828 and 0.827 for the hybrid three‐tier, four‐tier and five‐tier systems, respectively; all P < 0.001). The Hybrid 3‐Tier model achieved the most favourable AIC and BIC, while the five‐tier model yielded the highest C‐index (0.818). Conclusions: Hybrid grading systems improve progression‐risk stratification in non‐invasive papillary urothelial carcinoma compared with WHO 2004/2016, with most benefit achieved by the Hybrid 3‐Tier framework. These findings support the concept of a histomorphological continuum of progression risk and favour continued refinement of biologically informed hybrid grading for NMIBC risk stratification.


  • TFE-Altered Renal Cell Carcinoma: A Contemporary Review With Practical Insights and Diagnostic Pearls for Surgical Pathologists

    by Christopher G. Przybycin, Jane K. Nguyen, Reza Alaghehbandan

    Since the initial recognition of unique renal cell carcinomas (RCC) with the ASPCR1::TFE3 gene fusion, the category of MiT-family RCC has evolved to include TFE3 -rearranged RCC, TFEB -rearranged RCC, and TFEB -amplified RCC, 3 entities with significant intracategory and intercategory variation in morphology and clinical behavior. Given their ability to mimic one another as well as more common RCC subtypes, we present a review here that summarizes relevant morphologic, immunohistochemical, and molecular findings as well as a practical approach to diagnosis. Accurate diagnosis of TFE-altered RCCs is critical to provide patients and treating clinicians with pertinent prognostic information and inform treatment decisions in the event of advanced disease.


  • In reply to: ‘Prostate cancer with favorable histology is not synonymous with prostate cancer indolence’

    by Jesse K McKenney, James D Brooks, Jane K Nguyen, C K Cornelia Ding, Lisa F Newcomb, Jonathan L Myles, Reza Alaghehbandan, Christopher G Przybycin, Emily Chan, Jeffry P Simko, et al.


  • Open Access

    Classification of prostatic adenocarcinoma as favourable/unfavourable histology has high interobserver agreement in prostate needle core biopsies

    by Chien‐Kuang C Ding, Huijun Xiao, Jane K Nguyen, Christopher G Przybycin, Reza Alaghehbandan, Jonathan L Myles, Nancy Y Greenland, Jeffry P Simko, Deepika Sirohi, Bradley A Stohr, et al.

    Aims: A dichotomous classifier for prostatic adenocarcinoma, favourable and unfavourable histology, was recently proposed to optimize metastasis prediction. We evaluate interobserver agreement for its classification.Methods and results: Fifty biopsies with prostatic adenocarcinoma were selected. One slide per biopsy was scanned using the Aperio AT2 scanner (20x) and viewed in Leica Web Viewer. Ten pathologists reviewed each slide after completing a training module. Biopsies were scored for Grade Group (1–5) and presence of unfavourable histology. Forty‐one of 50 biopsies (82%) had unanimous consensus [13 (32%) unfavourable and 28 (68%) favourable], 47 (94%) for at least 9 of 10 reviewers, and 48 (96%) for at least 8 of 10 reviewers. Percent agreement for favourable/unfavourable classification was 94%, kappa = 0.88 (95% CI: 0.8, 0.96), and Gwet's AC1 coefficient = 0.90 (95% CI: 0.82, 0.97) [both P‐value < 0.001]. Inter‐rater agreement for Grade Group designation was evaluated in biopsies with 100% consensus. In the favourable consensus group (n = 28), kappa for Grade Group was 0.80 (95% CI: 0.62, 0.98) and Kendall's W was 0.83 (95% CI: 0.81, 0.89), with both P‐value < 0.001. For the unfavourable consensus group (n = 13), kappa for Grade Group was 0.56 (95% CI: 0.36, 0.75) and Kendall's W was 0.78 (95% CI: 0.76, 0.85), with both P‐value < 0.001.Conclusions: The classification of prostatic adenocarcinoma as favourable/unfavourable histology has high interobserver agreement, even when learnt through a simple tutorial. GG designation was more variable. This provides evidence that the favourable/unfavourable classification could be utilized in routine practice given its ease of use.


  • Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature

    by Anandi Lobo, Katrina Collins, Seema Kaushal, Andres M Acosta, Mahmut Akgul, Amit K Adhya, Hikmat A Al‐Ahmadie, Khaleel I Al‐Obaidy, Ali Amin, Mahul B Amin, et al.

    Aims: Urothelial carcinoma (UC) demonstrates significant molecular and histologic heterogeneity. The WHO 2022 classification has hinted at adding molecular signatures to the morphologic diagnosis. As morphology and associated molecular repertoire may potentially translate to choices of and response to therapy and relapse rate, broader acceptability of recognizing these key features among uropathologists is needed. This prompted an international survey to ascertain the practice patterns in classical/subtype UC among uropathologists across the globe.Methods and Results: A survey instrument was shared among 98 uropathologists using SurveyMonkey software. Anonymized respondent data were analysed. The response rate was 85%. A majority were in concordance with the profiles of luminal (93%) and basal (82%) types. Opinion on the FGFR3 testing platform was variable. While 95% concurred that TERT promoter mutation is the key driver in UC, 72% had the opinion that APOBEC mutagenesis is the main signature in muscle invasive bladder cancer (MIBC). Uropathologists have divergent opinions on MIBC and ERCC2 mutations. Among the participants, 94% would quantify aggressive micropapillary and sarcomatoid histology, while 88% would reevaluate another transurethral resection of the bladder tumour specimen in nonmuscle invasive tumour with micropapillary, small cell, or sarcomatoid histology. A leading number agreed to specific molecular signatures of micropapillary (93%), plasmacytoid (97%), and small cell (86%) subtypes. Ninety‐six percent of participants agreed that a small‐cell component portends a more aggressive course and should be treated with neoadjuvant chemotherapy and 63% would perform HER2/neu testing only on oncologist's request in advanced tumours. Ninety percent agreed that microsatellite instability testing, although not a standard protocol, should be considered in young patients with upper tract UC. Eighty‐six percent agreed that UC with high tumour mutational burden would be a better candidate for immunotherapy.Conclusion: In the era of precision medicine, enhanced understanding of molecular heterogeneity of UC will contribute to better therapeutic options, novel biomarker discovery, innovative management protocols, and outcomes. Our survey provides a broad perspective of pathologists' perceptions and experience regarding incorporation of histomolecular approaches to “personalize” therapy. Due to variable clinical adoption, there is a need for additional data using uniform study criteria. This will drive generation of best practice guidelines in this area for widespread and consistent clinical utility.


  • MDM2 amplification in malignant Brenner tumors may play a role in progression to malignancy and aid in separation from urothelial and other ovarian carcinomas

    by Sindhu Shetty, Omar Habeeb, Christine Rivera, Caroline Astbury, Christopher Przybycin, Amy S. Joehlin-Price


  • Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma

    by Hari P. Dhakal, Jesse K. McKenney, Li Yan Khor, Jordan P. Reynolds, Cristina Magi-Galluzzi, Christopher G. Przybycin

    Clear cell papillary renal cell carcinoma (CCPRCC) was recently included in the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia as a subtype of RCC that is morphologically, immunohistochemically, and genetically distinct from both clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma. In our clinical practice we have observed tumors with overlapping histologic features of CCPRCC and CCRCC; therefore, our aim was to describe the morphologic, immunohistochemical, and clinical characteristics of these tumors. We examined a large series of consecutive nephrectomies diagnosed as CCRCC and found 37 tumors with morphologic overlap between CCRCC and CCPRCC, identifying 2 patterns. Pattern 1 tumors (N=19) had areas diagnosable as CCRCC admixed with foci having a prominent linear arrangement of nuclei away from the basement membrane imparting a resemblance to CCPRCC; however, other morphologic features commonly seen in CCPRCC (such as branching acini and cystic spaces with papillary tufts) were not typical and, when present, were focal or poorly developed. Pattern 2 (N=18) tumors had 2 discrete areas, one area with an appearance strongly resembling CCPRCC and the other with higher grade nuclei and features diagnosable as CCRCC, sometimes including rhabdoid differentiation, sarcomatoid differentiation, necrosis, and high-stage disease. Four (21%) of the pattern 1 tumors had grade 3 nuclei in the CCRCC-like areas, and 4 were high stage (pT3a). Of the 16 immunostained pattern 1 tumors, all expressed cytokeratin 7 (CK7) at least focally in the CCPRCC-like areas, strongly and diffusely in 9 (56%) cases; 12 (75%) showed negative to focal and/or weak CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, high–molecular-weight cytokeratin, and carbonic anhydrase IX (CA IX) had no significant differential expression between these foci. No cup-like staining pattern was seen with CA IX. Two (11%) patients with pattern 1 tumors developed metastases, and 1 (5%) subsequently died of disease. Eleven (61%) pattern 2 cases had the International Society of Urological Pathology grade 3 nuclei in the CCRCC-like areas, and 7 (39%) were grade 4 (4 of these cases had rhabdoid features; 1 was also sarcomatoid). Of the 16 immunostained pattern 2 tumors, 8 (50%) showed strong diffuse CK7 expression in the CCPRCC-like areas, and 9 (56%) showed complete lack of CK7 expression in the CCRCC-like areas. CD10, α-methylacyl-CoA-racemase, and high-molecular-weight cytokeratin did not have significant differential expression. Membranous expression of CA IX, typically strong and diffuse, was identified in both the CCPRCC-like and CCRCC-like areas in all cases tested (with a cup-like pattern at least focally in the CCPRCC-like areas of 10 [63%] pattern 2 cases). Five (28%) patients with pattern 2 tumors had distant metastases, 3 (17%) of whom subsequently died of disease. Renal cell carcinomas with areas resembling both CCRCC and CCPRCC occur. Some can have high-grade and high-stage foci, and aggressive clinical outcomes are seen. Given this malignant potential, we would presently diagnose such cases as CCRCC. These 2 patterns of renal neoplasia underscore the need for caution in diagnosing CCPRCC on limited sampling, reserving the diagnosis for those tumors that strictly fulfill both morphologic and immunohistochemical criteria.